Filtered By:
Drug: Rosuvastatin
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 116 results found since Jan 2013.

Statin Therapy in Ischemic Stroke Models: A Meta-Analysis
AbstractStatins, drugs known for lipid lowering capabilities and reduction of cardiovascular disease, have demonstrated neuroprotective effects following ischemic stroke in retrospective clinical and animal studies. However, dosing (methods, time, type of statin, and quantity) varies across studies, limiting the clinical applicability of these findings. Furthermore, a comprehensive review of statins in edema and blood-brain barrier (BBB) breakdown is needed to provide insight on diverse, less explored neuroprotective effects. In the present study, we conduct a meta-analysis of publications evaluating statin administration ...
Source: Translational Stroke Research - December 1, 2019 Category: Neurology Source Type: research

Statins in stroke.
Conclusion: Treatment with statins prevents ischemic stroke, especially in patients with high cardiovascular risk and established atherosclerotic disease. It seems that both lipid lowering and pleiotropic effects contribute to these effects. PMID: 31218948 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - June 18, 2019 Category: Chemistry Authors: Aznaouridis K, Masoura C, Vlachopoulos C, Tousoulis D Tags: Curr Med Chem Source Type: research

Treatment with statins and ischemic stroke severity: Does the dose matter?
Conclusion: Pretreatment with statins is associated with lower stroke severity, at high as well as at low to moderate doses.
Source: Neurology - May 6, 2013 Category: Neurology Authors: Martinez-Sanchez, P., Fuentes, B., Martinez-Martinez, M., Ruiz-Ares, G., Fernandez-Travieso, J., Sanz-Cuesta, B. E., Cuellar-Gamboa, L., Diaz-Dominguez, E., Diez-Tejedor, E. Tags: ARTICLE Source Type: research

Statin and dual antiplatelet therapy for the prevention of early neurological deterioration and recurrent stroke in branch atheromatous disease: a protocol for a prospective single-arm study using a historical control for comparison
Introduction Branch atheromatous disease (BAD) contributes to small-vessel occlusion in cases of occlusion or stenosis of large calibre penetrating arteries, and it is associated with a higher possibility of early neurological deterioration (END) and recurrent stroke in acute ischaemic stroke. As the pathology of BAD is due to atherosclerosis, we postulate that early intensive medical treatment with dual antiplatelet therapy (DAPT) and high-intensity statins may prevent END and recurrent stroke in acute small subcortical infarction caused by BAD. Methods and analysis In this prospective, single-centre, open-label, non-ran...
Source: BMJ Open - November 26, 2021 Category: General Medicine Authors: Huang, Y.-C., Lee, J.-D., Weng, H.-H., Lin, L.-C., Tsai, Y.-H., Yang, J.-T. Tags: Open access, Neurology Source Type: research

Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
AbstractPurpose of ReviewThe aim of this study is to investigate the protective effects of different statin classes, intensity, and cumulative dose-dependent against primary ischemic stroke in patients with T2DM.Recent FindingsThe Cox hazards model was used to evaluate statin use on primary ischemic stroke. Case group: T2DM patients who received statins; control group: T2DM patients who received no statins during the follow-up. Adjusted hazard ratio (aHR) for primary ischemic stroke was 0.45 (95% CI: 0.44 to 0.46). Cox regression analysis showed significant reductions in primary ischemic stroke incidence in users of differ...
Source: Current Atherosclerosis Reports - July 29, 2023 Category: Cardiology Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - December 29, 2022 Category: Drugs & Pharmacology Source Type: research

Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study
ConclusionAmong patients treated with a statin following ischemic stroke, the risk of intracranial hemorrhage is not influenced by statin lipophilicity.
Source: Drug Safety - June 15, 2017 Category: Drugs & Pharmacology Source Type: research

Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale  and design
ConclusionThe CEIRIS trial about the effects of statin on the temporal hemodynamic progression of ICAS may extend our understanding of the basic pathophysiology and mechanisms of stroke in ICAS patients. With the use of computed tomography perfusion, we aim to evaluate the impact of Rosuvastatin on cerebral hemodynamic changes, as well as the downstream perfusion. This trial concerning the effects of statin on the temporal hemodynamic progression of intracranial atherosclerotic stenosis (ICAS) may extend our understanding of the basic pathophysiology and mechanisms of stroke in ICAS patients.
Source: Brain and Behavior - April 1, 2017 Category: Neurology Authors: Xuting Zhang, Ying Zhou, Sheng Zhang, Wenhong Ding, Min Lou Tags: METHODS Source Type: research

A comparison of safety and efficacy between long-term DAPT and intensive statins combined with short-term DAPT for acute ischemic stroke
ConclusionsCompared to long-term DAPT, intensive rosuvastatin with short-term DAPT was equivalent in reducing the risk of recurrent ischemic stroke. It alleviated symptoms more rapidly, and significantly reduced the risk of bleeding, without causing an increase in transaminase or muscle enzymes.Clinical trial registrationChina Clinical Trial Registration Center (ChiCTR1800017809)
Source: European Journal of Medical Research - April 21, 2023 Category: Research Source Type: research

Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease
Abstract After careful review of randomized cardiovascular outcomes trial data, the 2013 ACC/AHA cholesterol guideline focused on using the appropriate intensity of statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk and moved away from recommending specific low-density lipoprotein cholesterol (LDL-C) treatment targets. In patients who have had a stroke or other clinical ASCVD event, a high-intensity statin should be initiated up to age 75 years unless there are safety concerns, including a history of hemorrhagic stroke. A moderate-intensity statin is recommended if there are safety conc...
Source: Current Neurology and Neuroscience Reports - February 2, 2016 Category: Neuroscience Source Type: research

Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial
ConclusionThe INSPIRE study indicated that intensive statin therapy may not improve clinical outcomes compared with the low dose of statin therapy in AIS patients undergoing intravenous thrombolysis, and the two groups had similar safety profile.Clinical trial registrationURL:http://www.chictr.org. Unique identifier: ChiCTR-IPR-16008642
Source: Journal of Neurology - February 8, 2021 Category: Neurology Source Type: research

Long-Term Use of Statins Lowering the Risk of Rehospitalization Caused by Ischemic Stroke Among Middle-Aged Hyperlipidemic Patients: A Population-Based Study
Conclusion: Statins were associated with long-term secondary prevention of reHospIS for hyperlipidemic patients. Rosuvastatin seemed to have the best protective effects. On the other hand, Bezafibrate appears to be beneficial for hyperlipidemic patients developing diabetes. Further research into the combination treatment of statin and nonstatin lipid-lowering medicines in hyperlipidemic patients developing diabetes is warranted.
Source: Frontiers in Pharmacology - October 18, 2021 Category: Drugs & Pharmacology Source Type: research

PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging
BMJ Open. 2022 Apr 29;12(4):e060068. doi: 10.1136/bmjopen-2021-060068.ABSTRACTINTRODUCTION: Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin-kexin type 9 and effectively lower low-density lipoprotein cholesterol levels with less side effects than statins. We hypothesise that alirocumab treatment in addition to statin therapy could stabilise intracranial plaque and reduce arterial stenosis.METHODS AND ANALYSIS: In this pro...
Source: Atherosclerosis - April 29, 2022 Category: Cardiology Authors: Yen-Chu Huang Chia-Hao Chang Yuan-Hsiung Tsai Hsu-Huei Weng Leng-Chieh Lin Jiann-Der Lee Source Type: research